DexCom price target raised to $154 from $140 at Raymond James

Raymond James analyst Jayson Bedford raised the firm’s price target on DexCom to $154 from $140 and keeps a Strong Buy rating on the shares. DexCom’s Q2 results were in line, with a “surprise” coming from international growth and margins, as operating profits were up more than 50% y/y, the analyst tells investors in a research note. Q3 represents the first full quarter of basal coverage, which is the core near-term value driver in the U.S., the firm says.